The American College of Cardiology and the American Heart Association today released a new clinical practice guideline for the treatment of blood cholesterol¹（胆固醇） in people at high risk for cardiovascular diseases caused by atherosclerosis（动脉粥样硬化）, or hardening and narrowing of the arteries², that can lead to heart attack, stroke or death. The guideline identifies four major groups of patients for whom cholesterol-lowering HMG-CoA reductase inhibitors, or statins, have the greatest chance of preventing stroke and heart attacks. The guideline also emphasizes the importance of adopting a heart-healthy lifestyle to prevent and control high blood cholesterol.

 

"The new guideline uses the highest quality scientific evidence to focus treatment of blood cholesterol on those likely to benefit most," said Neil J. Stone, MD, Bonow professor of medicine at Northwestern University Feinberg School of Medicine and chair of the expert panel that wrote the new guideline. "This guideline represents a departure from previous guidelines because it doesn't focus on specific target levels of low-density lipoprotein（脂蛋白） cholesterol, commonly known as LDL, or 'bad cholesterol,' although the definition of optimal³ LDL cholesterol has not changed. Instead, it focuses on defining groups for whom LDL lowering is proven to be most beneficial."

 

The new guideline recommends moderate- or high-intensity statin therapy for these four groups: Patients who have cardiovascular disease; Patients with an LDL, or "bad" cholesterol level of 190 mg/dL or higher; Patients with Type 2 diabetes⁴ who are between 40 and 75 years of age; and Patients with an estimated 10-year risk of cardiovascular disease of 7.5 percent or higher who are between 40 and 75 years of age (the report provides formulas for calculating 10-year risk). 

 

In terms of clinical practice, physicians can use risk assessment⁵ tools in some cases to determine which patients would most likely benefit from statin therapy, rather than focusing only on blood cholesterol to determine which patients would benefit.

 

"The likely impact of the recommendations is that more people who would benefit from statins are going to be on them, while fewer people who wouldn't benefit from statins（他汀类药物） are going to be on them," Dr. Stone said. Doctors may also consider switching some patients to a higher dose of statins to derive⁶ greater benefit as a result of the new guidelines.

 

The guideline was prepared by a panel of experts based on an analysis of the results of randomized controlled trials. The panel was charged with guiding the optimal treatment of blood cholesterol to address the rising rate of cardiovascular disease, currently the leading cause of death and disability in the U.S.

 

The panel chose to focus on the use of statins after a detailed⁷ review of other cholesterol-lowering drugs. "Statins were chosen because their use has resulted in the greatest benefit and the lowest rates of safety issues. No other cholesterol-lowering drug is as effective as statins," said Dr. Stone. He added that there is a role for other cholesterol-lowering drugs, for example, in patients who suffer side effects from statins.

 

The report also stresses the importance of lifestyle in managing cholesterol and preventing heart disease. "The cornerstone of all guidelines dealing⁸ with cholesterol is a healthy lifestyle," said Dr. Stone. "That is particularly important in the young, because preventing high cholesterol later in life is the first and best thing someone can do to remain heart-healthy. On the other hand, if someone already has atherosclerosis, lifestyle changes alone are not likely to be enough to prevent heart attack, stroke, and death, and statin therapy will be necessary."

点击收听单词发音